Clin Drug Invest. 2006;26(1):29-34. Conclusion: These results show that there is little or no potential for a clinically relevant pharmacokinetic interaction between olmesartan medoxomil 20mg and ...

Please provide your email address to receive an email when new articles are posted on . Combination azilsartan medoxomil and chlorthalidone was shown to be superior to combination olmesartan medoxomil ...

The therapeutic profile of olmesartan medoxomil, which is a recently developed angiotensin II (A II) receptor blocker, has been compared with four commonly used antihypertensive therapeutic drugs ...

Parsippany, NJ (May 27, 2005) – Data from two clinical studies presented at the American Society of Hypertension's Twentieth Annual Scientific Meeting (ASH 2005) in San Francisco demonstrated that ...

Olmesartan medoxomil is an angiotensin II (Ang II) receptor blocker (ARB) that has been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. It is a prodrug that is ...

Parsippany, NJ (May 26, 2004) – New data from two different clinical studies demonstrated that patients with hypertension can achieve more aggressive blood pressure goal rates using antihypertensive ...

Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB). Olmesartan Medoxomil and Hydrochlorothiazide combines an ARB with a thiazide diuretic. Olmesartan Medoxomil is indicated for the ...

Olmesartan Medoxomil is indicated for the treatment of high blood pressure or hypertension. It was developed by the Japanese pharmaceutical company Sankyo in 1995. Olmesartan is administered as an ...

Olmesartan medoxomil, hydrochlorothiazide; 20mg/12.5mg, 40mg/12.5mg, 40mg/25mg; tabs. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin ...

PARSIPPANY, N.J., June 16 A new study published in thecurrent Journal of the American Society of Hypertension demonstrates that thehypertension treatment olmesartan medoxomil was effective in ...

This was a randomised, open-label phase I study with a three-way crossover design, carried out at a single centre in Görlitz, Germany. The study was performed in accordance with the Declaration of ...